APTOSE BIOSCIENCES INC (APTO) Stock News
NASDAQ:APTO - Nasdaq - CA03835T4081 - Common Stock - Currency: USD
APTO Latest News, Press Relases and Analysis
Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial
Mentions: APS.CA
Aptose Announces Auditor Not Standing for Re-Appointment
Aptose Announces Auditor Not Standing for Re-Appointment ...
Mentions: APS.CA
Aptose Announces Auditor Not Standing for Re-Appointment
Mentions: APS.CA
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference...
Mentions: APS.CA
Why Aptose Biosciences (APTO) Stock Is Down Over 40%
Aptose Biosciences shares are trading lower by 53.7% during Tuesday's session. The company announced it is going to delist from the Nasdaq.
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
Mentions: APS.CA
Aptose Common Shares to Delist from Nasdaq as of April 2, 2025
Nasdaq to Delist Aptose Common Shares as of April 2, 2025...
Mentions: APS.CA
Aptose Common Shares to Delist from Nasdaq as of April 2, 2025
Mentions: APS.CA
Icon Energy to effect 1-for-40 reverse stock split
Icon Energy (ICON) announced an update on certain corporate matters and that its board of directors has determined to effect a 1-for-40 reverse stock split of the Company’s issued common shares par value $0.001 effective at the opening of trading on April 1, 2025. On January 24, 2025, the Company announced the closing of its $12M public offering of units containing Common Shares and warrants to purchase Common Shares, as set forth in more detail in the Company’s registration statement on Form F-
Milestone CRL affirms integrity of clinical data, says H.C. Wainwright
H.C. Wainwright keeps a Buy rating on Milestone Pharmaceuticals (MIST) after the company announced receipt of a complete response letter from the FDA regarding its new drug application for its etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia. While “disappointed,” the firm says the issues raised were exclusively related to chemistry, manufacturing, and controls, with no concerns cited around the clinical efficacy or safety of etripamil. This reaffirms the integr
Braze price target raised to $55 from $50 at Citi
Citi raised the firm’s price target on Braze (BRZE) to $55 from $50 and keeps a Buy rating on the shares after the company “delivered a strong finish to FY25” and gave FY26 organic growth guidance of 16%, which does not include the contribution from the OfferFit acquisition, that was better-than-expected. The company also announced it will acquire AI decisioning-engine startup OfferFit, which tripled revenue last year, leading the firm to “believe there is healthy room for upside to numbers,” th
Humacyte price target lowered to $8 from $10 at BTIG
BTIG lowered the firm’s price target on Humacyte (HUMA) to $8 from $10 and keeps a Buy rating on the shares post the Q4 report. The firm cites the company’s increased share count for the target cut. The analyst views Humacyte’s early commercial traction as evidence of the “game-changing nature” of its Acellular Tissue Engineered Vessel. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >>
Lulu’s Fashion Lounge price target lowered to $1 from $2 at Telsey Advisory
Telsey Advisory analyst Dana Telsey lowered the firm’s price target on Lulu’s Fashion Lounge (LVLU) to $1 from $2 and keeps a Market Perform rating on the shares. The company delivered an EBITDA beat for Q4, driven by better-than-expected gross margin performance and tighter expense control, the analyst tells investors. While the firm is encouraged by the company’s FY25 outlook for its adjusted EBITDA, the challenged topline hinders a more robust turnaround, the firm adds. Published first on The
Stock Split Watch: Are These 2 Unstoppable Stocks Next?
There is no science to predicting which companies will resort to a stock split and when, but observers can use some clues to make educated guesses. Stock splits help make a company's shares look more affordable. Are stock splits in the works for these corporations?
Aptose Reports Year End 2024 Results and Corporate Highlights
Mentions: APS.CA
Aptose Reports Year End 2024 Results and Corporate Highlights
Aptose Reports Year End 2024 Results and Corporate Highlights...
Mentions: APS.CA
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance...
Mentions: APS.CA
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
Mentions: APS.CA
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
Aptose Announces Positive Clinical Safety Review and Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib...
Mentions: APS.CA